A Clinical Cohort Study on the Pathogen Spectrum of Hepatic Virus-caused Cirrhosis Complicated With Infection
NCT ID: NCT06279845
Last Updated: 2024-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
2000 participants
OBSERVATIONAL
2024-03-31
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Describe the populations and characteristics of pathogenic microorganisms responsible for co-infections in patients with hepatic virus-caused cirrhosis.
* Map the spectrum of pathogenic microorganisms, and evaluate their impact on disease regression.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploring Clinical Characteristics of Liver Disease Patients Based on Digestive Metabolic Exhaled Air
NCT06968234
Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis
NCT05086536
Prospective Cohort Study of Complications and Outcomes in Cirrhosis
NCT06374511
Infections in Hospitalized Cirrhotic Patients
NCT03137719
Analysis of Clinical Features of Chronic Liver Disease Complicated With Hepatopulmonary Syndrome
NCT05932927
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Any gender and age between 18-70 years old;
3. HBsAg positivity lasting more than 6 months;
4. have clinical manifestations of hepatic decompensation and portal hypertension, laboratory test results, liver imaging or endoscopy and other comprehensive diagnosis of definite cirrhosis.
Exclusion Criteria
2. Patients who, in the opinion of the investigator, are not suitable for participation in the study.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Ditan Hospital
OTHER
Beijing YouAn Hospital
OTHER
Huashan Hospital
OTHER
Qilu Hospital of Shandong University
OTHER
Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jiajia Chen
Chief Physician of the First Affiliated Hospital,Zhejiang University School of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jiajia Chen
Role: PRINCIPAL_INVESTIGATOR
Zhejiang University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023YFC2308802-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.